Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals

Navani, 2022, Treatment selection in first-line metastatic renal cell carcinoma—the contemporary treatment paradigm in the age of combination therapy: a review, JAMA Oncol, 8, 292, 10.1001/jamaoncol.2021.4337 Ljungberg, 2022, European Association of Urology guidelines on renal cell carcinoma: the 2022 update, Eur Urol, 82, 399, 10.1016/j.eururo.2022.03.006 Graafland, 2022, Surgical safety of deferred cytoreductive nephrectomy following pretreatment with immune checkpoint inhibitor-based dual combination therapy, Eur Urol Oncol, 5, 373, 10.1016/j.euo.2021.11.004 Pignot, 2020, Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma: a new surgical challenge?, Eur Urol, 77, 761, 10.1016/j.eururo.2019.12.018 Singla, 2019, Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma, Urol Oncol, 37, 924, 10.1016/j.urolonc.2019.08.012 Dindo, 2004, Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey, Ann Surg, 240, 205, 10.1097/01.sla.0000133083.54934.ae Bhindi, 2019, Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma, Eur Urol, 75, 111, 10.1016/j.eururo.2018.09.016 Shirotake, 2022, Impact of cytoreductive nephrectomy following nivolumab plus ipilimumab therapy for patients with advanced renal cell carcinoma, Anticancer Res, 42, 2727, 10.21873/anticanres.15751 May, 2021, A contemporary analysis of the 30-day morbidity and mortality associated with cytoreductive nephrectomy, Urology, 147, 186, 10.1016/j.urology.2020.10.016 Motzer, 2020, Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial, J Immunother Cancer, 8, e000891, 10.1136/jitc-2020-000891